• Room 02.005 - CCRCB Block 5 MBC Site

    United Kingdom

Accepting PhD Students

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Paul Mullan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 64 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
asparaginylendopeptidase Medicine & Life Sciences
DNA Damage Medicine & Life Sciences
Ovarian Neoplasms Medicine & Life Sciences
Biomarkers Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Triple Negative Breast Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2012 2018

Research Output 2000 2019

Defining the molecular evolution of extrauterine high grade serous carcinoma

Beirne, J. P., McArt, D. G., Roddy, A., McDermott, C., Ferris, J., Buckley, N. E., Coulter, P., McCabe, N., Eddie, S. L., Dunne, P. D., O'Reilly, P., Gilmore, A., Feeney, L., Ewing, D. L., Drapkin, R. I., Salto-Tellez, M., Kennedy, R. D., Harley, I. J. G., McCluggage, W. G. & Mullan, P. B., 04 Sep 2019, In : Gynecologic Oncology. 155, 2, p. 305-317 13 p.

Research output: Contribution to journalArticle

Molecular Evolution
Fallopian Tubes
Carcinoma in Situ
1 Citation (Scopus)
Open Access
Tumor Microenvironment
Colorectal Neoplasms
Epithelial Cells
Bone Morphogenetic Proteins

Identification and SAR exploration of a novel series of Legumain inhibitors

Eddie, S. L., Gregson, A., Graham, E., Burton, S., Harrison, T., Burden, R., Scott, C. J., Mullan, P. B. & Williams, R., 15 Jun 2019, In : Bioorganic & Medicinal Chemistry Letters. 29, 12, p. 1546-1548 3 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer

Mullan, P. B., Bingham, V., Haddock, P., Irwin, G. W., Kay, E., McQuaid, S. & Buckley, N. E., 02 Apr 2019, In : BMC Cancer. 19, 13 p., 236.

Research output: Contribution to journalArticle

Open Access
Triple Negative Breast Neoplasms
Drug Therapy
Standard of Care
Breast Neoplasms
Protein Binding
Cell Proliferation
Co-Repressor Proteins


Development and Commercialization of a Technology Platform to Enable Biomarker Discovery and Validation

Richard Kennedy (Participant), Paul Harkin (Participant), Patrick Johnston (Participant), Alison Hosey (Participant), Julia Miskelly (Participant), Margaret Murray (Participant), Jennifer Quinn (Participant), Colin James (Participant), Jude Mulligan (Participant), Peter Daly (Participant), Paul Mullan (Participant), Julie Mussen (Participant), Ultan McDermott (Participant), Richard Wilson (Participant), Daniel Longley (Participant)

Impact: Health Impact, Quality of Life Impact